Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo

• Main Authors: Ya-nan Liu (Author), Xinhao Xu (Author), Jingjing Nie (Author), Yingying Hu (Author), Xuegu Xu (Author), Ren-ai Xu (Author), Xiaoxiang Du (Author)
• 格式: 圖書
• 出版: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience aspergillosis infection and they may start using isavucona...